ROCKWELL MEDICAL (RMTI) Company Report

Rockwell Medical expects preliminary net sales for Q4 2025 to be approximately $18.6 million and for the full-year 2025 to be approximately $69.5 million.
The company anticipates a gross margin of approximately 22% for Q4 2025, which is a notable improvement from 14% in Q3 2025.
Rockwell Medical expects to report cash flow from operations of approximately $2.3 million in Q4 2025, marking its second cash flow positive quarter in 2025.
Cash and cash equivalents and investments available-for-sale are expected to increase to approximately $25 million at December 31, 2025.
Mark Strobeck, President and CEO, stated that Q4 2025 reflects a considerable increase in revenue, being cash flow positive, and Adjusted EBITDA positive, with a focus on revenue growth, increased profitability, and portfolio diversification for 2026.

Jan 20, 2026, 11:32 AM

8-K

Rockwell Medical Reports Preliminary Q4 and Full-Year 2025 Financial Results

RMTI

Earnings

Guidance Update

Revenue Acceleration/Inflection

Rockwell Medical expects preliminary unaudited net sales for Q4 2025 to be approximately $18.6 million and for the full-year 2025 to be approximately $69.5 million.
The company anticipates a gross margin of approximately 22% in Q4 2025, an improvement from 14% in Q3 2025, and expects to report cash flow from operations of approximately $2.3 million in Q4 2025, marking its second cash flow positive quarter in 2025.
As a result of improved cash flow, cash and cash equivalents and investments available-for-sale are expected to increase to approximately $25 million at December 31, 2025.

Jan 20, 2026, 11:00 AM

Press Release

Rockwell Medical Adds 30 New Customers in the West

RMTI

New Projects/Investments

Revenue Acceleration/Inflection

Rockwell Medical has added 30 new customers in the western United States, expanding its customer clinic footprint in the region to more than 10% of its total.
This expansion is expected to generate multi-million dollars in revenue from the new west coast customer base.
The company rapidly scaled production and expanded its logistics infrastructure to address customer demand due to meaningful disruption in the hemodialysis concentrates supply chain, particularly in the western U.S..
Rockwell Medical is now a viable alternative supplier in the western U.S., able to more efficiently deliver hemodialysis concentrates products to both new and existing customers in the region.

Jan 12, 2026, 11:00 AM

Press Release

Rockwell Medical Extends Product Purchase Agreement

RMTI

Rockwell Medical has extended its Amended and Restated Product Purchase Agreement with one of the largest dialysis providers in the United States through December 31, 2026.
The extended agreement includes an increase in product pricing for the duration of the term.
Mark Strobeck, Ph.D., President and CEO of Rockwell Medical, stated that the renewal reflects the critical role of the company's reliable supply chain and high-quality hemodialysis products.

Jan 5, 2026, 11:00 AM

Press Release

Rockwell Medical Reports Q3 2025 Results and Strategic Progress

RMTI

Earnings

Guidance Update

New Projects/Investments

Rockwell Medical (RMTI) reported net sales of $15.9 million for Q3 2025, a 44% decrease compared to Q3 2024, but achieved positive Adjusted EBITDA of $50,000, an improvement from previous quarters.
The company is successfully managing the transition of its largest customer, which accounted for 12% of Q3 2025 net sales, and has strengthened its contract portfolio with over 80% of customers now under long-term agreements.
Adjusted gross margin for Q3 2025 was 18% (excluding restructuring costs), and the company ended the quarter with a strong cash position of $23.7 million, which it plans to use for business development opportunities and potential acquisitions.
Operational efficiency efforts, including a facility closure, are expected to be substantially completed by year-end, with further impact on operating expenses anticipated in Q4.

Nov 12, 2025, 1:00 PM

Transcript

Rockwell Medical Reports Q3 2025 Results, Achieves Adjusted EBITDA Profitability

RMTI

Earnings

Guidance Update

New Projects/Investments

Rockwell Medical reported net sales of $15.9 million for Q3 2025 and achieved adjusted EBITDA of $50,000, reflecting profitability on an adjusted EBITDA basis.
The company's gross margin, excluding restructuring costs, improved to 18% in Q3 2025.
The transition of its formerly largest customer, which accounted for 12% of net sales in Q3 2025, is anticipated to be resolved this quarter, with over 80% of customers now under long-term agreements.
Rockwell Medical ended Q3 2025 with $23.7 million in cash, cash equivalents, and investments, and is actively pursuing business development, including potential acquisitions, and expanding its bicarbonate cartridge and West Coast presence.

Nov 12, 2025, 1:00 PM

Transcript

Rockwell Medical Reports Q3 2025 Financial Results

RMTI

Earnings

Guidance Update

New Projects/Investments

Rockwell Medical reported net sales of $15.9 million for Q3 2025 and achieved adjusted EBITDA of $50,000, marking profitability on an adjusted basis and an improvement over previous quarters.
The company's gross margin for Q3 2025 was 14%, or 18% excluding restructuring costs, with a net loss of $1.8 million.
Cash, cash equivalents, and investments available for sale increased to $23.7 million as of September 30, 2025, up from $18.4 million at the end of Q2 2025.
Rockwell Medical is actively managing the transition of its largest customer, which accounted for 12% of Q3 2025 net sales, and expects a resolution in Q4 2025.
Strategic progress includes strengthening its contract portfolio with over 80% of customers under long-term agreements, optimizing its organizational structure, and securing new customer agreements, alongside the launch of a higher-margin bicarbonate cartridge. The company plans to provide 2026 revenue guidance with its Q4 earnings release and is pursuing business development and acquisition opportunities.

Nov 12, 2025, 1:00 PM

Transcript

Rockwell Medical announces Q3 2025 results and reiterates 2025 guidance

RMTI

Earnings

Guidance Update

Demand Weakening

Rockwell Medical reported net sales of $15.9 million for the third quarter ended September 30, 2025, which represents a 44% decrease over the same period in 2024, primarily driven by the Company's largest customer transitioning to another supplier.
The company achieved profitability on an Adjusted EBITDA basis for the third quarter 2025, with Adjusted EBITDA reaching $50,000.
Cash, cash equivalents, and investments available-for-sale increased to $23.7 million at September 30, 2025, up from $18.4 million at June 30, 2025.
Rockwell Medical reiterated its 2025 annual guidance, expecting net sales between $65.0 million and $70.0 million, gross margin between 16% and 18%, and Adjusted EBITDA between ($0.5) million and $0.5 million.